238 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Paternal Expressed Gene 10 (PEG10) is decreased in early-onset preeclampsia
3. Assessment of the tocolytic nifedipine in preclinical primary models of preterm birth
4. Plasma lipids are dysregulated preceding diagnosis of preeclampsia or delivery of a growth restricted infant
5. Can single-cell and spatial omics unravel the pathophysiology of pre-eclampsia?
6. Cell surface associated protein mucin 15 (MUC15) is elevated in preeclampsia
7. Placental DAAM2 is unaltered in preeclampsia, but upregulated by treatment with proton pump inhibitors
8. The effect of metformin on cardiovascular markers in female mice consuming a high fat diet
9. Exploring the Therapeutic Potential of C-Type Natriuretic Peptide for Preeclampsia.
10. LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast
11. Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia
12. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction
13. DAAM2 is elevated in the circulation and placenta in pregnancies complicated by fetal growth restriction and is regulated by hypoxia
14. Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria
15. NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast
16. Circulating trace elements for the prediction of preeclampsia and small for gestational age babies
17. Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia
18. Disulfiram inhibits placental soluble FMS-like tyrosine kinase-1 and soluble endoglin secretion independent of the proteasome
19. EGFL7 gene expression is regulated by hypoxia in trophoblast and altered in the plasma of patients with early preeclampsia
20. Effect of sildenafil citrate on circulating levels of sFlt-1 in preeclampsia
21. MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia
22. Circulating mRNAs are differentially expressed in pregnancies with severe placental insufficiency and at high risk of stillbirth
23. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction
24. Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin
25. The Regulation of Endothelin-1 in Pregnancies Complicated by Gestational Diabetes: Uncovering the Vascular Effects of Insulin.
26. Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
27. A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
28. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
29. Quantitative Point of Care Tests for Timely Diagnosis of Early‐Onset Preeclampsia with High Sensitivity and Specificity.
30. Circulating Chemerin Is Elevated in Women With Preeclampsia.
31. Investigating the Effects of Atrial Natriuretic Peptide on the Maternal Endothelium to Determine Potential Implications for Preeclampsia.
32. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks’ gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study
33. Expression of Myostatin in Intrauterine Growth Restriction and Preeclampsia Complicated Pregnancies and Alterations to Cytokine Production by First-Trimester Placental Explants Following Myostatin Treatment
34. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model.
35. Chorioamnionitis Occurring in Women With Preterm Rupture of the Fetal Membranes Is Associated With a Dynamic Increase in mRNAs Coding Cytokines in the Maternal Circulation
36. Endothelial protein C receptor is increased in preterm preeclampsia and fetal growth restriction.
37. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health.
38. Placental galectin-3 is reduced in early-onset preeclampsia.
39. New generation antiplatelet agents for the prevention of preeclampsia: enhancing antioxidant pathways in first trimester placenta.
40. Elucidating the function of Sialic acid-binding immunoglobulin-like lectin-6 (SIGLEC6) in preeclampsia.
41. Neuronal cell adhesion molecule (NrCAM) is reduced in pregnancies with small for gestational age.
42. Cystatin 6 (CST6) and Legumain in preeclampsia.
43. Purinergic signalling in the human placenta and functional analysis of purinoceptor P2Y6 in placental development.
44. A global approach to advancing prediction of preeclampsia pathogenesis.
45. High glucose availability alters the proteomic profile of small placental extracellular vesicles and their ability to induce endothelial dysfunction.
46. Eplerenone: A candidate drug to mitigate long-term maternal vascular dysfunction following preeclampsia.
47. Serum Collected from Preeclamptic Pregnancies Drives Vasoconstriction of Human Omental Arteries—A Novel Ex Vivo Model of Preeclampsia for Therapeutic Development.
48. Assessment of the Proton Pump Inhibitor, Esomeprazole Magnesium Hydrate and Trihydrate, on Pathophysiological Markers of Preeclampsia in Preclinical Human Models of Disease.
49. Placental OLAH Levels Are Altered in Fetal Growth Restriction, Preeclampsia and Models of Placental Dysfunction.
50. Transcriptional profiles of genes related to mitochondrial aging in placental pathologies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.